Priced Out of Prevention

Weight loss drugs like GLP-1s have exposed a deep divide in how employers think about preventative health care, and who gets to decide what counts as medically necessary versus elective. John Baldino and Jackye Clayton dig into the real cost of prevention, from insurance denials and weight bias to what happens when companies opt out of covering it altogether.

Key Takeaways:

• GLP-1 medications sit in a gray area between elective and medically necessary care, and insurers are still deciding where that line falls
• Employers on level-funded or self-insured plans can see utilization data, which puts real decision-making power over coverage in HR's hands
• Weight bias shows up in coverage decisions, with some plans opting out of any weight-loss support entirely
• Preventative care decisions made today, like a child's activity level or an employee's untreated conditions, compound into much larger health costs later
• Companies like Bank of America have reported real productivity and engagement benefits from covering GLP-1 medications
• Medication alone isn't the full answer, behavioral support and habit change matter just as much as the prescription
• The majority of Americans get health insurance through their employer, which puts most coverage decisions in the hands of HR and finance leaders, not doctors
• Rising premiums are pushing employers toward harder trade-offs between covering preventative care and controlling costs
• Trusting employees and their physicians to make care decisions is becoming harder as organizations lean more on data and utilization review
• Open enrollment timing makes this a live decision for many employers right now, not a hypothetical for later

Keywords: GLP-1 coverage, preventative care, employee health benefits, self-insured health plans, weight bias, open enrollment, health insurance costs, employer health care, workplace wellness, HR benefits strategy